All News
ACR 2022 - Day 1 Report
The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.
Read Article
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Read Article
McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent manner @RheumNow #ACR22 Abstr#1805 https://t.co/aGg5i5XyTK https://t.co/x8ChwASM6P
Richard Conway RichardPAConway ( View Tweet)
Johnson et al. VA matched cohort study. 560,000 gout patients, 5.4 million controls. Gout asoc with increased CV risk of 68% HF hospitalization, 25% HF-related death, 22% MACE. Poor SU control assoc CVD events. @RheumNow #ACR22 Abstr#1580 https://t.co/CBSMFRpg82 https://t.co/6IS3Cozjzs
Richard Conway RichardPAConway ( View Tweet)
Black et al. Treat to target in gout. Monthly rheumatologist review and urate titration vs 6-monthly. 89% vs 40% at target ≤0.30mmol/L (<5mg/dl). SU decrease 38% vs 18%. US features also improved. @RheumNow #ACR22 Abstr#1579 https://t.co/TvxWAtl83y
Richard Conway RichardPAConway ( View Tweet)
Data like this make us think even in the setting of a controlled clinical trial in #gout, non-white patients much less likely to achieve target serum urate!
Black pts 70% less likely to reach target compared to whites!
#ACR22 @RheumNow abst#1583 https://t.co/dYet7pk2l5
Bella Mehta bella_mehta ( View Tweet)
Protective effect of #allopurinol in gout
Dose dependent reduction in risk of acute coronary syndrome in incident #Gout
#ACR22 @RheumNow abst#1582 https://t.co/PrEtRwvLvm
Bella Mehta bella_mehta ( View Tweet)
Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about this. We should drink more sake it seems! @RheumNow #ACR22 Abstr#1206 https://t.co/En5pSMUNp7 https://t.co/c67r9fsHJT
Richard Conway RichardPAConway ( View Tweet)
Adding MTX to Pegloticase for 52 wks in gout
◦ Improved response rate by 30%
◦ Reduced discontinuation rate by 40%
◦ Greater resolution of tophi by 20%
◦ Similar safety profile in MTX vs non-MTX groups
Botson J, MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow https://t.co/le9ggUa2Xk
Dr. Antoni Chan synovialjoints ( View Tweet)
This work can lay foundation to so much more!
#ArtificialIntelligence and #naturallanguageprocessing on Facebook private #gout groups
- Mental health mentioned in 4% of all posts/comments
- primary care asso with “trust” and urgent care with “fear”
@RheumNow #ACR22 abst#0201 https://t.co/fSuOeNGWvg
Bella Mehta bella_mehta ( View Tweet)
Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU <6mg/dl. Infusion reaction 13% vs 32% if ab+ 0% vs 30% ab- @RheumNow #ACR22 Abstr#0001 #ACRbest https://t.co/1c3Va9NxNX https://t.co/dPGDyWue4G
Richard Conway RichardPAConway ( View Tweet)
Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089
Continued under-reporting of race and ethnicity in PsA trials. Abs 0090
We can do better #rheumtwitter
#ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abst#0001 MIRROR RCT at #ACR22 #plenary
Pts with gout on #pegloticase and #gout
sustained higher urate lowering response in pts cotreated with #MTX
benefit beyond 6 months
@rheumnow https://t.co/rTZ3fPaFJS
Bella Mehta bella_mehta ( View Tweet)
🪞MIRROR RCT🪞
💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%)
🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻)
🧪⬇️ drug Ab with MTX
✅ No new IRs
Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC
Patricia Harkins DrTrishHarkins ( View Tweet)
Excellent start to the first plenary session!
MIRROR study - MTX coadministration with pegloticase for gout treatment
- doubling of efficacy and 7x decrease in infusion reactions
- less anti-PEG abs
@RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO
Robert B Chao, MD doctorRBC ( View Tweet)
MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4
Dr. Rachel Tate uptoTate ( View Tweet)
Role of acquired mutations in #gout
Risk factor for gout CHIP?
Individuals with CHIP are more likely to developed acute episodes of gouty episodes
More IL-1B in cells with somatic mutations like CHIP
@rheumnow #ACR22 #yearinreview https://t.co/k3VeZuTCln
Bella Mehta bella_mehta ( View Tweet)
CHIP- need to know! Somatic mutations fondly known as CHIP - not the salty ones. Clonal hematopoeisis of uncertain significance. Older Pts getting somatic mutations account for more CVS, malignancies , one change in TET2 increased gout #ACR2022 @RheumNow John Barga Yr in Review https://t.co/6bnqnkDFpL
Janet Pope Janetbirdope ( View Tweet)
MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia...
@RheumNow #ACR22 #yearinreview
Julian Segan JulianSegan ( View Tweet)
